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Abstract
During the development of type 2 diabetes, endoplasmic reticulum (ER) stress leads to not
only insulin resistance but also to pancreatic beta cell failure. Conversely, cell function
under various stressed conditions can be restored by reducing ER stress by activating
AMP-activated protein kinase (AMPK). However, the details of this mechanism are still
obscure. Therefore, the current study aims to elucidate the role of AMPK activity during ER
stress-associated pancreatic beta cell failure. MIN6 cells were loaded with 5-amino-1-β-D-
ribofuranosyl-imidazole-4-carboxamide (AICAR) and metformin to assess the relationship
between AMPK activity and CCAAT enhancer binding protein β (C/EBPβ) expression lev-
els. The effect of C/EBPβ phosphorylation on expression levels was also investigated.
Vildagliptin and metformin were administered to pancreatic beta cell-specific C/EBPβ
transgenic mice to investigate the relationship between C/EBPβ expression levels and
AMPK activity in the pancreatic islets. When pancreatic beta cells are exposed to ER stress,
the accumulation of the transcription factor C/EBPβ lowers the AMP/ATP ratio, thereby
decreasing AMPK activity. In an opposite manner, incubation of MIN6 cells with AICAR or
metformin activated AMPK, which suppressed C/EBPβ expression. In addition, administra-
tion of the dipeptidyl peptidase-4 inhibitor vildagliptin and metformin to pancreatic beta cell-
specific C/EBPβ transgenic mice decreased C/EBPβ expression levels and enhanced pan-
creatic beta cell mass in proportion to the recovery of AMPK activity. Enhanced C/EBPβ
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Introduction
Pancreatic beta cell mass can be affected negatively by events that disrupt cellular homeostasis,
such as oxidative stress or autophagic dysfunction. In particular, endoplasmic reticulum (ER)
stress due to obesity and systemic insulin resistance is one important pathogenic factor that
might lead to pancreatic beta cell failure [1,2]. However, the details of ER stress-related beta
cell failure and onset of diabetes are obscure.
The CCAAT enhancer-binding protein (C/EBP) family of basic leucine-zipper transcription
factors includes C/EBPα, -β, -γ, -δ, and -ε, as well as C/EBP homology protein (CHOP) [3]. C/
EBPβ performs diverse functions, including the regulation of genes that contribute to the acute
phase response, glucose metabolism, and tissue differentiation, including adipogenesis and
hematopoiesis [4]. We have shown that the transcription factor C/EBPβ, which is expressed at
low levels under normal circumstances, is highly induced by ER stress in pancreatic beta cells
[5]. The accumulation of C/EBPβ weakens these cells against ER stress and reduces pancreatic
beta cell mass by inhibiting induction of the molecular chaperone 78-kDa glucose-regulated
protein (GRP78), which is the major ER chaperone in all eukaryotes that enables the essential
process of productive folding in the ER [6–9]. More recently, it has been reported that accumu-
lation of C/EBPβ is also observed in the pancreatic beta cells of type 2 diabetes patients but is
not found in patients with normal glucose tolerance [10]. Elucidation of the mechanisms that
control C/EBPβ expression is therefore important to discovering novel therapeutic targets for
ameliorating pancreatic beta cell failure.
AMP-activated protein kinase (AMPK) is activated by a decrease in cellular energy (an ele-
vation of the AMP/ATP ratio) and restores ATP levels by deactivating biosynthetic pathways
and activating catabolism. AMPK activation reportedly reduces ER stress and rescues beta cell
function in a cellular model of glucotoxicity [11]. It is noteworthy that C/EBPβ expression is
highly sensitive to AMPK activation in the liver [12]. These reports led us to hypothesize that
differential interaction between AMPK and C/EBPβmay be key to determining the fate of pan-
creatic beta cells exposed to ER stress.
In this study, we demonstrated that during the onset of type 2 diabetes, pancreatic beta cells
exhibit enhanced C/EBPβ expression along with decreased AMPK activity, which forms a
vicious cycle that reduces pancreatic beta cell mass.
Materials and Methods
Mice
Pancreatic beta cell-specific C/EBPβ transgenic (TG) mice with a C57BL/6J background were
generated and maintained as described previously [5,13,14]. Male wild-type and C/EBPβ TG
mice were grouped and housed with access to either regular water or water continuously sup-
plemented with metformin (LSG Corporation, Tokyo, Japan) and/or 0.6 mg/mL vildagliptin (a
gift from the Novartis Institutes for BioMedical Research, Cambridge, MA, USA) from 4 to 12
weeks of age. Mice were sacrificed after the study by cervical dislocation. This study was
approved by the Animal Ethics Committee of Kobe University Graduate School of Medicine
(approval number P130508).
C/EBPβ and AMPK in Pancreatic βCells
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Cell culture and transfection of siRNA
MIN-6 cells were maintained in Dulbecco’s modified Eagle's medium supplemented with 15%
heat-inactivated fetal bovine serum and 1% penicillin/streptomycin. For overexpression of
C/EBPβ, MIN-6 cells were transfected with expression plasmid carrying the full C/EBPβ by
using Lipofectamine 3000 (Invitrogen) transfection reagent. For knockdown of AMPK, MIN-6
cells were re-plated in 12-well plates (60-mm dishes) at 24 h before transfection and transfected
with siRNA for AMPKα1 and α2 (SMARTpool; Dharmacon, Lafayette, CO) or scramble
controls (Non-Targeting siRNA#2; Dharmacon) with DharmaFECT2 transfection reagent
(Dharmacon). After 48 h of further incubation for 48 h for protein, cells were harvested for
evaluation of C/EBPβ expression.
Oral glucose tolerance test
Mice were deprived of food for 16 h prior to the oral administration of glucose (1.5 mg/g body
weight). Blood was collected immediately before and at 15, 30, 45, 60, and 120 min after glu-
cose administration.
Islet isolation
Pancreatic islets were isolated by collagenase digestion and hand-picked under a stereoscope as
previously described [14,15].
Immunostaining and morphometric analysis
The pancreas was immersed in Bouin’s solution, embedded in paraffin, and sectioned at a
thickness of 4–5 μm. Sections were stained with antibodies against insulin and glucagon (Dako
Japan, Kyoto, Japan). Immune complexes were detected using secondary antibodies conjugated
to either Cy3 or FITC (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Quan-
titation of beta cell mass was performed as described previously [13].
Immunoblot analysis
Lysates of the isolated islets and C/EBPβ-overexpressing MIN6 cells were prepared as described
previously [5,14] and probed with antibodies against phosphorylated (p)-C/EBPβ (Thr235:
equivalent to Thr188 of the mouse sequence; Cell Signaling, Danvers, MA, USA), C/EBPβ,
CHOP (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), p-AMPK (Thr172), AMPK,
c-Myc, acetyl-CoA carboxylase (ACC), p-ACC, eukaryotic translation initiation factor 2α
(eIF2α), p-eIF2α, p-c-jun (Cell Signaling Technology, Danvers, MA, USA) anti-human influ-
enza hemagglutinin (Roche Applied Science, Mannheim, Germany), and β-actin (Sigma-
Aldrich, St. Louis, MO, USA). Quantitative analysis of blots was performed with Multi Gauge
Version 3.0 software (Fujifilm, Tokyo, Japan), and protein levels were normalized to the β-
actin levels.
Plasmid construction
C/EBPβmutant vectors (T188A, E) were prepared by cloning wild-type mouse C/EBPβ (35
kDa isoform) cDNA into the pBABE vector. The mutants were generated using a PrimeSTAR
Mutagenesis Basal Kit (Takara Bio, Inc., Otsu, Japan). pcDNA3 vectors containing wild-type
or dominant negative (DN) (K45R) AMPK were obtained from Addgene (Plasmids #15991
and #15992; Cambridge, MA, USA). The pcDNA3 vector containing the constitutively active
(CA) (T172D) AMPK sequence was a gift of David Carling (Imperial College, London, UK).
All cDNA sequences were further cloned into the pBABE vector.
C/EBPβ and AMPK in Pancreatic βCells
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Metabolomic analysis
For metabolite extraction, 450 μl MilliQ water containing internal standards (methionine sul-
fone and camphor-10-sulfonic acid), 500 l CHCl3, and 250 μl methanol were added to 30 mg
tissue or 300 pancreatic islets, and the mixture was homogenized by a bead mill homogenizer.
After centrifugation, the supernatant was collected, filtered using a 5-kDa cutoff filter, and
freeze-dried. The hydrophilic metabolites were subjected to capillary electrophoresis-mass
spectrometry on an Agilent capillary electrophoresis coupled to time-of-flight mass spectrome-
try (7100 CE and 6224 TOF LC/MS). Metabolite concentrations were calculated as the ratio
between each metabolite in the sample and the standard compounds.
Statistical analysis
Results are expressed as the mean ± standard error. Statistical significance was assessed with
ANOVA and, when appropriate, Student’s t test. A P value of< 0.05 was considered statisti-
cally significant.
Results
Enhanced C/EBPβ expression caused by ER stress decreases AMPK
activity
The effect of ER stress on AMPK activity was investigated. When MIN6 cells were exposed to
tunicamycin, AMPK activity, indicated by levels of p-AMPK and p-ACC, was significantly
inhibited (Fig 1A). As mentioned previously, C/EBPβ expression in ordinary conditions is
minimal, but was significantly enhanced by ER stress in pancreatic beta cells concomitant with
increased levels of p-eIF2α and CHOP (Fig 1A) [5]. We examined the possibility that C/EBPβ,
the expression of which is enhanced by ER stress, affects AMPK activity. Overexpression of
empty vector in MIN6 cells did not affect the expression of C/EBPβ and ER stress markers (Fig
1B upper left) and the efficiency of transient transfection was dependent on the amount of C/
EBPβ DNA used for transfection (Fig 1B, lower left). Overexpression of C/EBPβ in MIN6 cells
also caused a significant reduction of AMPK activity, as indicated by the decreased phosphory-
lation of AMPK and ACC (Fig 1B, middle and right).
We established pancreatic beta cell-specific C/EBPβ TGmice, as previously described [5].
The TG mice did not exceed glucose levels of about 200 mg/dL, indicating that the effect of
hyperglycemia remained minimal [16]. Pancreatic islets isolated from TG mice showed signifi-
cantly decreased AMPK phosphorylation. Taken together, we believe this findings indicate that
the reduced AMPK phosphorylation was caused not by hyperglycemia, but rather by accumu-
lation of C/EBPβ (Fig 1C).
To elucidate the link between AMPK activity and C/EBPβ, we evaluated AMP and ATP lev-
els by metabolomic analysis. Compared with wild-type, islets from the TG group had signifi-
cantly lower AMP levels, but no significant change in ATP levels (Fig 1D). As a result, the
AMP/ATP ratio was significantly lowered. Thus, when pancreatic beta cells are exposed to ER
stress, C/EBPβ accumulates, lowering the AMP/ATP ratio and AMPK activity.
C/EBPβ expression levels are dependent on AMPK activity
We next examined the effect of AMPK activity on C/EBPβ expression levels in pancreatic beta
cells. MIN6 cells were transfected with a C/EBPβ expression vector and subsequently stimu-
lated with 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR). The elevated
AMPK activity was accompanied by a decrease in C/EBPβ expression (Fig 2A). Similarly, met-
formin also reduced C/EBPβ expression (Fig 2B). Next, the effect of AMPK on C/EBPβ
C/EBPβ and AMPK in Pancreatic βCells
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Fig 1. Accumulation of C/EBPβ due to ER stress lowers AMPK activity. A: MIN6 cells were treated with 1 μg/mL tunicamycin (Tm) for 24 h and analyzed
with the indicated antibodies (left). Quantitation of the AMPK phosphorylation level is normalized to total AMPK (right). B: MIN6 cells were transfected with C/
EBPβ expression vectors or empty vector. The cells were analyzed with the indicated antibodies (left and middle). Quantitation of the AMPK phosphorylation
level is normalized to total AMPK (right). C: Isolated islets from wild-type (WT) and TGmice at 12 weeks of age were analyzed with the indicated antibodies
C/EBPβ and AMPK in Pancreatic βCells
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expression levels was investigated directly with HA-tagged C/EBPβ and c-Myc-tagged C/EBPβ.
The exogenous C/EBPβ used here has three HA tags, which was expected to produce a differ-
ence of approximately 9 kDa in band mobility (Fig 2C, right). Therefore, judging by the mobil-
ity, the band visible in Lanes 1, 3, and 4 in Fig 2C, next to the exogenous C/EBPβ band (47
kDa) in Lanes 2, 4, and 6, are likely to be non-specific and not a band for endogenous C/EBPβ
(38 kDa). When C/EBPβ was co-expressed with DN-AMPK, C/EBPβ levels were significantly
increased compared with wild-type AMPK co-expression. Moreover, C/EBPβ co-expression
with CA-AMPK resulted in significantly reduced C/EBPβ levels (Fig 2C, left and middle). We
examined the endogenous C/EBPβ band, and found that normal endogenous C/EBPβ expres-
sion levels were low and that no changes were observed even during the coexpression of
WT-AMPK; however, when DN-AMPK was coexpressed a slight increase in C/EBPβ expres-
sion was noted. Conversely, when CA-AMPK was coexpressed, a slight decrease was observed
(Fig 2C, right). To further confirm the effect of AMPK on the expression of C/EBPβ, we estab-
lished AMPK knockdown MIN6 cells, where AMPK was knocked down with siRNA. AMPK
protein was significantly reduced by approximately 50% at the protein level, and phosphoryla-
tion of AMPK and ACC was subsequently reduced (Fig 2D, leftmost and second left). As
expected, a reduction of AMPK expression created an increase in C/EBPβ expression (Fig 2D,
rightmost and second right). Isolated islets were then used to analyze the in vivo effects of vil-
dagliptin on TG mice. AMPK phosphorylation, which was decreased in the pancreatic islets of
TG mice (Fig 1C and 1D), was significantly increased by vildagliptin (Fig 2E). This enhanced
AMPK phosphorylation was thought to be a key factor in the reduction of C/EBPβ expression.
Phosphorylation is required for the stabilization of C/EBPβ
Regarding the mechanism by which AMPK regulates C/EBPβ levels, we hypothesized that
AMPK might modulate the phosphorylation status of C/EBPβ. The effect of 1-(5-isoquinoline-
sulfonyl)-2-methylpiperazine (H7), which is a serine/threonine kinase inhibitor, on C/EBPβ-
overexpressing MIN6 cells was therefore investigated. Endogenous C/EBPβ levels were
increased after tunicamycin treatment, but C/EBPβ induction was abolished in the presence of
H7 (Fig 3A). Next, the effects of H7 on protein stability in C/EBPβ-overexpressing MIN6 cells
were investigated. H7 also significantly reduced the levels of overexpressed C/EBPβ (Fig 3B).
The impact of inhibiting C/EBPβ expression was almost entirely restored with a proteasome
inhibitor, Cbz-Leu-Leu-leucinal (MG132) (Fig 3B). Thus, when the serine/threonine residues
of C/EBPβ are phosphorylated, proteasome-mediated degradation of C/EBPβ is inhibited, lead-
ing to its accumulation. We then examined the relationship between C/EBPβ levels and its
phosphorylation status. Increased C/EBPβ levels in MIN6 cells after tunicamycin treatment
were found to be accompanied by C/EBPβ T188 phosphorylation (Fig 3C). Extracellular sig-
nal-regulated kinase (ERK) and p38 are known kinases of C/EBPβ T188 [17,18]; therefore, the
impact of ERK and p38 on C/EBPβ overexpression was investigated. C/EBPβ levels were
decreased by an ERK inhibitor (U0126), but not by a p38 inhibitor (SB203580) (Fig 3D). This
suggested that serine/threonine kinases play an important role in the protein stability of C/
EBPβ, a role that is played in part through ERK.
(left). Quantitation of the AMPK phosphorylation level is normalized to total AMPK (right). D: Isolated islets fromWT and TGmice at 12 weeks of age were
analyzed for AMP and ATP levels by LC/MS. Data are means ± SE of 3 independent experiments. *P < 0.05, **P < 0.01. n.s., not significant.
doi:10.1371/journal.pone.0130757.g001
C/EBPβ and AMPK in Pancreatic βCells
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Fig 2. C/EBPβ expression is inhibited when AMPK is activated pharmacologically. A, B: MIN6 cells were transfected with expression vectors for C/
EBPβ. The cells were incubated with 100 μMAICAR (A) or 500 μMmetformin (B) for 24 h and analyzed with the indicated antibodies (left). Quantitation of C/
EBPβ expression is normalized to β-actin (right). C: MIN6 cells were transfected with expression vectors for c-Myc-tagged AMPK, CA-AMPK, DN-AMPK,
and/or human influenza hemagglutinin epitope-tagged C/EBPβ, as indicated. These transfected cells were analyzed with the indicated antibody (left and
right). Quantitation of C/EBPβ expression is normalized to β-actin (middle). D: MIN6 cells treated with scramble siRNA (control) and AMPK siRNA were lysed
and subjected to immunoblot analysis with antibodies against AMPK, ACC, p-AMPK, p-ACC, and C/EBPβ. E: Isolated islets fromWT and TGmice following
8 weeks of vildagliptin (vilda) treatment were analyzed with the indicated antibodies (left). Quantitation of the AMPK phosphorylation level is normalized to
total AMPK (right). Data are means ± SE of 3 (C, D) or 4 (A, B, E) independent experiments. *P < 0.05, **P < 0.01.
doi:10.1371/journal.pone.0130757.g002
C/EBPβ and AMPK in Pancreatic βCells
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Fig 3. C/EBPβ phosphorylation is required for protein stabilization. A: MIN6 cells were incubated with
2 μg/mL tunicamycin and/or 20 μMH7. B: MIN6 cells were transfected with expression vectors for C/EBPβ
and then incubated with 20 μMH7 and 20 μMMG132. C: MIN6 cells were incubated with 5 μg/mL
tunicamycin for the indicated periods. C/EBPβ expression and the phosphorylation of C/EBPβ at Thr-188
were analyzed by western blot analysis. D: MIN6 cells were transfected with expression vectors for C/EBPβ
and then incubated with 20 μMU0126 and 20 μMSB203580 (left). Quantitation of C/EBPβ expression is
normalized to β-actin (right) (n = 3). *P < 0.05, **P < 0.01. n.s., not significant.
doi:10.1371/journal.pone.0130757.g003
C/EBPβ and AMPK in Pancreatic βCells
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AMPK destabilizes C/EBPβ via T188 dephosphorylation
A non-phosphorylatable mutant (T188A) was generated to investigate the role of T188 phos-
phorylation in C/EBPβ stability. When C/EBPβ and DN-AMPK were co-expressed, C/EBPβ
expression levels were further increased (Figs 2C and 4A). However, this effect was not observed
when T188A or T188E mutant C/EBPβ was co-expressed with DN-AMPK (Fig 4A). When wild-
type C/EBPβ and CA-AMPK were co-expressed, C/EBPβ levels were reduced, but this was not
the case with the T188A or T188E mutant C/EBPβ (Fig 4B). This suggested that AMPK activa-
tion leads to the dephosphorylation of C/EBPβ T188, thereby destabilizing C/EBPβ, and that
inactivation of AMPK increased C/EBPβ levels via the phosphorylation of T188.
AMPK activity was decreased under ER stress (Fig 1A). In addition to the known increased
transcription of C/EBPβ under ER stress, we examined the effects of ER stress on C/EBPβ sta-
bility. We evaluated the effect of the ER-stress inducer thapsigargin separately for endogenous
(C/EBPβ) and exogenous (HA-C/EBPβ) expression levels. Both were increased by thapsigargin
treatment, but that this effect on the endogenous C/EBPβ expression was weaker than that on
the HA-C/EBPβ (Fig 4C, left). To examine the possibility that this increase in exogenous C/
EBPβ expression is due to improvements in protein stability, we assessed C/EBPβ expression
levels after cycloheximide treatment. Cycloheximide treatment of C/EBPβ-overexpressing cells
with or without HA-tag reduced C/EBPβ protein levels, but not in cells that were co-stimulated
with thapsigargin (Fig 4C, middle and right). In contrast, endogenous C/EBPβ expression did
not increase even when stimulation with thapsigargin was performed after cycloheximide treat-
ment in the presence of HA-C/EBPβ (Fig 4C, upper-middle). This seems to be due to the inhi-
bition of endogenous protein synthesis associated with cycloheximide treatment.
However, no stabilizing action of ER stress on C/EBPβ was observed with T188A (Fig 4D).
This suggested that AMPK also plays a role in the increased stability of C/EBPβ under ER stress.
Metformin has no effect on glucose tolerance in pancreatic beta cell-
specific C/EBPβ TGmice
C/EBPβ accumulation in pancreatic beta cells subjected to ER stress is one of the factors leading
to pancreatic beta cell failure and the onset of diabetes [5]. Under such circumstances, we
hypothesized that AMPK activity would also be decreased, and that a potential enhancement
of AMPK activity in vivomight help to reduce C/EBPβ levels. We therefore investigated the
effects of metformin, an AMPK agonist, on C/EBPβ expression levels and pancreatic beta cell
mass in TG mice. The treatment had no significant impact on the food intake or body weight
of either wild-type or TG mice (data not shown). As reported previously [5,16], TG mice exhib-
ited mild hyperglycemia (Fig 5A), and insulin levels were also lowered in comparison to the
wild-type animals (Fig 5B). Metformin administration significantly lowered blood glucose lev-
els 2 weeks after treatment compared with the control group, although not significantly there-
after (Fig 5A). Fed insulin levels were unaffected by metformin (Fig 5B). An oral glucose
tolerance test revealed impaired glucose tolerance and reduced plasma insulin levels in TG
mice as compared with the wild-type animals. However, no significant difference was observed
between wild-type and TG mice after metformin treatment (Fig 5C and 5D). This suggested
that metformin has no effect on glucose tolerance in the TG mice.
Metformin has no effect on AMPK activity and a slight effect on C/EBPβ
expression levels in pancreatic beta cell-specific C/EBPβ TGmice
AMPK activity was assessed using isolated islets. In the islets of TG mice, AMPK activity was
reduced in comparison to the wild-type animals (Fig 6A and 6B). Administration of metformin
C/EBPβ and AMPK in Pancreatic βCells
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Fig 4. AMPK destabilizes C/EBPβ via T188 dephosphorylation. A: MIN6 cells were co-transfected with expression vectors for C/EBPβ, T188A-mutant C/
EBPβ, or T188E-mutant and mock or DN-AMPK (leftmost and second right). Quantitation of C/EBPβ expression is normalized to β-actin (second left and
rightmost). B: MIN6 cells were co-transfected with expression vectors for C/EBPβ or T188A-mutant C/EBPβ, T188E-mutant and mock or CA-AMPK (leftmost
and second right). Quantitation of C/EBPβ expression is normalized to β-actin (second left and rightmost). C, D: MIN6 cells were transfected with expression
vectors for C/EBPβ or HA-tagged C/EBPβ. The cells were pretreated with 1 μg/mL CHX and incubated with 1 μg/mL CHX and 1 μM thapsigargin. C/EBPβ
(C) or T188A-mutant C/EBPβ (D) expression was measured by western blot analysis (C; left and middle, D; left). Quantitation of C/EBPβ expression is
normalized to β-actin (right). Data are means ± SE of 3 independent experiments. *P < 0.05, **P < 0.01. n.s., not significant.
doi:10.1371/journal.pone.0130757.g004
C/EBPβ and AMPK in Pancreatic βCells
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had no impact on AMPK activity in wild-type mice as well as TG mice (Fig 6A and 6B). C/
EBPβ, which showed enhanced expression in the islets of the TG mice, was slightly reduced by
metformin administration (Fig 6A and 6C). Pancreatic beta cell mass, which was reduced in
the TG mice, was largely unaffected by metformin administration (Fig 6D and 6E). This sug-
gested that when metformin is administered to TG mice, there is no recovery of AMPK activity
and a mild reduction of C/EBPβ expression levels. However, we were unable to identify a sig-
nificant impact on pancreatic beta cell mass.
Combined use of metformin and vildagliptin ameliorates glucose
tolerance in pancreatic beta cell-specific C/EBPβ TGmice
Previously, we showed that C/EBPβ expression in the islets is reduced and pancreatic beta cell
mass is increased when vildagliptin is administered to TG mice concomitantly with ameliora-
tion of ER stress and restoration of insulin signaling [16]. Moreover, vildagliptin administra-
tion to TG mice recovers islet AMPK phosphorylation (Fig 2D). We therefore tested the
combination of metformin with vildagliptin for further enhancement of AMPK
Fig 5. Effect of metformin on glucose tolerance in pancreatic beta cell-specific C/EBPβ TGmice. A: Blood glucose levels and B: plasma insulin
concentrations during the 8-week treatment period (n = 10–16 per group). C: Blood glucose levels and D: plasma insulin levels after an oral glucose load
(1.5 mg/g body weight) following 8 weeks of metformin (met) treatment (n = 10–13 per group). *P < 0.05.
doi:10.1371/journal.pone.0130757.g005
C/EBPβ and AMPK in Pancreatic βCells
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phosphorylation. Accordingly, both wild-type and TG groups were administered vildagliptin,
and these groups were divided into four groups: those who were administered metformin and
those who were not. The combined use of metformin and vildagliptin did not significantly
affect body weight (data not shown). Compared with vildagliptin alone, the fed blood glucose
Fig 6. Metformin has no significant impact on AMPK activity or pancreatic beta cell mass in pancreatic beta cell-specific C/EBPβ TGmice. A:
Western blot analysis of islets isolated from TGmice following 8 weeks of metformin (met) treatment for analysis with the indicated antibodies. B: Quantitation
of the AMPK phosphorylation level is normalized to total AMPK in A (n = 4 per group). C: Quantitation of C/EBPβ expression in A (n = 3 per group). D:
Immunofluorescence staining of pancreas sections for insulin (red) and glucagon (green) following 8 weeks of metformin administration. Magnification
bar = 100 μm. E: Quantification of beta cell mass in WT and TGmice (n = 5–7 per group). *P < 0.05, **P < 0.01. n.s., not significant.
doi:10.1371/journal.pone.0130757.g006
C/EBPβ and AMPK in Pancreatic βCells
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levels of the TG mice were significantly reduced in the combined drug group up to and includ-
ing 4 weeks of administration; however, no difference was observed after 6 weeks of treatment
(Fig 7A). Insulin levels showed no significant difference between the vildagliptin alone and
combined drug groups (Fig 7B). An oral glucose tolerance test showed a significant improve-
ment in glucose tolerance and insulin secretion in the combined drug group compared with
the vildagliptin alone group (Fig 7C and 7D).
Combined use of metformin and vildagliptin increases pancreatic beta
cell mass in pancreatic beta cell-specific C/EBPβ TGmice
AMPK activity was assessed using isolated islets. When vildagliptin was administered to
the TG mice, AMPK activity was elevated compared with the TG mice without vildagliptin
Fig 7. Effect of the combined use of metformin and vildagliptin on glucose tolerance in pancreatic
beta cell-specific C/EBPβ TGmice. A: Blood glucose levels and B: plasma insulin concentrations during
the 8-week treatment period (n = 11–15 per group). C: Blood glucose levels and D: plasma insulin levels after
an oral glucose load (1.5 mg/g body weight) following 8 weeks of vildagliptin (vilda) and/or metformin (met)
treatment (n = 5–11 per group). WT-(vilda), open triangles; WT-(vilda+met), open diamonds; TG-(vilda), black
triangles; and TG-(vilda+met), black diamonds. *P < 0.05, **P < 0.01.
doi:10.1371/journal.pone.0130757.g007
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(Fig 2D), but in combination with metformin, AMPK activity was elevated even more than
with vildagliptin alone (Fig 8A and 8B). In addition, in the TG mice, the combined-metformin
group had even further reduced C/EBPβ expression levels than with vildagliptin alone (Fig 8A
Fig 8. Effect of combined use of metformin and vildagliptin on the islets in pancreatic beta cell-specific C/EBPβ TGmice. A: Western blot analysis of
islets isolated from TGmice following 8 weeks of vildagliptin (vilda) and/or metformin (met) treatment for analysis with the indicated antibodies. B:
Quantitation of the AMPK phosphorylation level is normalized to total AMPK in A (n = 4 per group). C: Quantitation of C/EBPβ expression in A (n = 4 per
group). D: Immunofluorescence staining of pancreas sections for insulin (red) and glucagon (green) following 8 weeks of vildagliptin and/or metformin
administration. Magnification bar = 100 μm. E: Quantification of beta cell mass in WT and TGmice (n = 6–7 per group). *P < 0.05, **P < 0.01.
doi:10.1371/journal.pone.0130757.g008
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and 8C), although vildagliptin treatment decreased C/EBPβ expression [16]. The combined-
metformin group also had a further increase of pancreatic beta cell mass compared with vilda-
gliptin treatment alone (Fig 8D and 8E), although vildagliptin treatment increased beta cell
mass [16]. In summary, compared with vildagliptin monotherapy, its combination with met-
formin further increased AMPK activity and reduced C/EBPβ levels in the islets of the TG
mice, thus further increasing pancreatic beta cell mass.
Discussion
The present study shows that when C/EBPβ expression is enhanced by ER stress, AMPK activ-
ity is decreased due to the lower AMP/ATP ratio. Moreover, this decreased AMPK activity
results in the accumulation of C/EBPβ by enhancement of protein stability. Decreased AMPK
activity and enhanced C/EBPβ expression might form a vicious cycle that leads to pancreatic
beta cell failure.
AMPK is considered an evolutionarily conserved sensor of cellular energy status [19–21].
AMPK is activated by pathological stresses such as low glucose [22], hypoxia [23], ischemia
[24], and oxidative stress [25]. Metformin exerts its pharmacological action via AMPK activa-
tion [26]. In pancreatic beta cells, the effect of AMPK on pancreatic beta cell mass is unclear
and remains controversial [27–30]. However, pancreatic beta cell function impaired by glucose
toxicity can reportedly be restored by reducing ER stress by activating AMPK [11].
Opinion is divided regarding whether AMPK activation is reduced [31] or elevated [32] in
cells in such a damaged condition. Considering the fact that AMPK acts protectively on cells
when activated, AMPK activity is likely reduced or its activation inadequate. We therefore
exposed MIN6 cells to ER stress to examine changes in AMPK activity, showing that AMPK
activity was reduced. As mentioned above, when pathological stresses activate AMPK for a
brief period, the decreased ATP and elevated AMP levels are regarded as being an important
factor [33], but it is thought that the accumulation of C/EBPβ following chronic ER stress cre-
ates a situation in which AMPK activity is inhibited.
We then investigated whether the modification of phosphorylation affects C/EBPβ stability.
In particular, Thr188 was reportedly the most important residue with regard to the stability of
C/EBPβ in adipocytes [34].
In our investigation, MIN6 cells subjected to ER stress increased C/EBPβ expression, which
was accompanied by T188 phosphorylation. T188 phosphorylation was shown to play an
important role in the stabilization of C/EBPβ by ER stress or AMPK inhibition. AMPK report-
edly inhibits ERK activity when activated [35], indicating that AMPK could inhibit T188 phos-
phorylation via inhibition of ERK expression.
The accumulation of C/EBPβ brought about by ER stress forms a vicious cycle with the low-
ering of AMPK activity, resulting in the reduction of pancreatic beta cell mass. We showed that
administering vildagliptin restored AMPK activity in TG mice. GLP-1 signaling reportedly
reduces NASH levels in the liver by enhancing AMPK activity [36,37]. This action is thought
to be cAMP-independent [38], and the impact of GLP-1 signaling on AMPK activity needs to
be examined. Our investigation also suggests that GLP-1 signaling might have a role in restor-
ing AMPK activity in pancreatic beta cells. Future investigations will have to address whether
this action is direct or a consequence of ER stress mitigation [39].
We also showed that the oral administration of metformin produced no significant
improvement in AMPK activity in the islets of TG mice. However, in combination with vilda-
gliptin, AMPK activation was significantly higher than with vildagliptin alone and brought
about a greater inhibition of C/EBPβ expression, along with an increase in pancreatic beta cell
mass. These findings demonstrate in vivo that the drugs enhance pancreatic beta cell survival
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by breaking the vicious cycles created by ER stress, C/EBPβ accumulation, and reduced AMPK
activity.
In summary, as type 2 diabetes progresses, pancreatic beta cells display decreased AMPK
activity along with enhanced C/EBPβ expression, and finally beta cell failure and the onset of
diabetes. Part of the protective action of existing anti-diabetes drugs on pancreatic beta cells
may therefore be brought about by interrupting the vicious cycle of ER stress, C/EBPβ accumu-
lation, and reduced AMPK activation. T188 phosphorylation of C/EBPβmay well be one of the
factors involved in this vicious cycle. A better understanding of the interactions between these
factors is essential to clarifying the molecular mechanisms involved in pancreatic beta cell fail-
ure. Reduction of C/EBPβ levels in pancreatic beta cells is regarded as perhaps being capable of
becoming a novel target of treatment that could result in the protection of pancreatic beta cells
from ER stress.
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